A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control
GnRH antagonist and GnRH agonist are widely used as androgen deprivation therapy for metastatic prostate cancer. A previous report demonstrated that patients with PSA levels of >20 ng/mL using GnRH antagonists showed favorable outcomes in comparison to those using GnRH agonists. An 82-year old...
I tiakina i:
| Ngā kaituhi matua: | , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Karger Publishers
2019-09-01
|
| Rangatū: | Case Reports in Oncology |
| Ngā marau: | |
| Urunga tuihono: | https://www.karger.com/Article/FullText/502859 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|